Piramal Enterprises (PEL) reported its first-ever positive quarterly PAT as an NBFC – at Rs35.5bn, well above our estimates. This was its second quarterly result as an NBFC post the demerger of Piramal Pharma. PAT was led by one-offs in terms of: i) income tax provision reversal of Rs33.3bn.